TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02811887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise
Description: A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants allocated to usual care will receive instructions related to healthy living, alcohol absenteeism, and benefits of increased physical activity. The instructions will be provided by a physical therapist and/or a nurse, and will be given according to recommendations and local and national guidance. The participants are offered continued regular visits at the rehabilitation clinic, but no supervised physical exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS-messages
Description: Participants allocated to SMS-messages will receive the same intervention as usual care (see above) AND regular text messages via SMS over a 12-week period.~The text messages will be unidirectional and will serve as motivational information but will not allow two-way communication with a researcher or health professional about clinical management. The messages will provide information, motivation, and support to adhere to a healthy lifestyle, alcohol absenteeism, and physical activity and will reinforce the information and instructions received at the face-to-face information (usual care).
Study: NCT04921267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training
Description: training with filtered speech
Study: NCT01537432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: secukinumab
Study: NCT01967667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liposomal glutathione
Description: Escalating dose steps

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: escalating dose steps
Study: NCT01689207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avibactam (AVI)
Description: PART A: AVI IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam (ATM)
Description: PART A: ATM IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of Aztreonam - Avibactam (ATM-AVI)
Description: PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PART A, PART B, PART C: matching placebo IV infusions
Study: NCT04423926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10mg/d#15mg/d#20mg/d#25mg/d d1\~d10# 21days a cycle
Study: NCT01537432

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study: NCT03412955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: 1.4mg/m2/dose on days 1 and 8 of a 21-day treatment cycle.
Study: NCT01765387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spa session
Study: NCT02921867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Description: The simulation-based training will consist of nine modules that can be trained in random order and training periods within the eight weeks before clinical training starts.
Study: NCT00938626

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
Description: After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
Study: NCT04423926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 mg/m2 d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m2 d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4mg/m2 (maximum 2mg) d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 60mg/m2 d1-5
Study: NCT00938626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
Study: NCT00245479

Intervention type: DRUG
Group type: OTHER
Intervention: Primary nocturnal enuresis
Description: Desmopressin
Study: NCT04480866

Intervention type: DEVICE
Group type: OTHER
Intervention: Colli-Pee® (FV5000 and Small Volumes)
Description: Colli-Pee® device (Novosanis, Belgium) attached to collector tubes prefilled with a non-toxic nucleic acid preservative (including an internal process control). The collector tubes differ in size to collect a total sample volume of 4, 10, and 20 mL.~Each participant will collect three urine samples using the Colli-Pee Small Volumes 4 and 10 mL, and the Colli-Pee FV5000 (20 mL) device, in a random order.
Study: NCT00057148

Intervention type: PROCEDURE
Group type: OTHER
Intervention: massage treatment
Study: NCT02168556

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Subject listens to music that is 60bpm while undergoing urodynamic testing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Subject watches an informational video prior to undergoing urodynamic testing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study: NCT04418245

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging by thoracic scanner
Description: Low-dose computed tomography
Study: NCT01537328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total knee replacement rehabilitation
Description: After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement rehabilitation
Description: After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
Study: NCT02902614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vegetal Pole blastomer embryo
Description: for day 3 embryo biopsy / cleavage stage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vegetal Pole blastomer embryo
Description: for day 3 embryo biopsy / cleavage stage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Animal Pole blastomer embryo
Description: for day 3 embryo biopsy / cleavage stage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Animal Pole blastomer embryo
Description: for day 3 embryo biopsy / cleavage stage
Study: NCT03224884

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Ultrasound guided brachial plexus block injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in the interscalene groove, under the prevertebral fascia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supraclavicular block
Description: Ultrasound guided brachial plexus injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL (3 mL in the corner pocket followed by 17 mL posterolateral to the brachial plexus).
Study: NCT03341936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
Study: NCT00296712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram + bupropion
Description: same dosing as for monotherapy arms
Study: NCT01146002

Intervention type: DRUG
Group type: OTHER
Intervention: Guanfacine (sustained release)
Description: Treated with study drug once screening and initial testing is completed (see protocol above)
Study: NCT04843592

Intervention type: DEVICE
Intervention: SOKARY Mobile
Description: Effectiveness of using SOKARY Mobile Application on compliance of patient with Type II diabetes
Study: NCT02538796

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEA + Grober Test + Task 1 + Grober Test
Description: The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEA + Grober Test + Task 1 + Grober Test
Description: The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words.
Study: NCT02221700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Undergo massage therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Undergo massage therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Undergo massage therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Undergo massage therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04118101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESPB block
Description: A total of 25 ml bupivacaine 0.5% will be injected into the ESP.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no ESPB will be given.
Study: NCT02171728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Study: NCT00480532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lybrel
Description: All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lybrel
Description: All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oracea
Description: 40-mg tablet daily for 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100bid x5 days at the time of bleeding
Description: Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subantimicrobial doxycycline daily
Description: Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo daily
Description: Placebo daily for the first 84 days of the study
Study: NCT02221700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01285102

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: irinotecan-eluting beads
Description: Patients will be treated with drug-eluting irinotecan beads per protocol at up to 100 mg per dose every 3 weeks. Patients will receive chemoembolization using LC Bead, loaded with irinotecan. The beads size range used in the study will be 100-300µm (nominal) with a dose of up to 100mg irinotecan per treatment. The beads will be mixed with a non-ionic contrast media in the vial immediately prior to use according to the instructions for use. Irinotecan will be loaded onto the beads not more than 2 hours prior to the procedure. The study goal will be to deliver the full dose of 100mg of irinotecan per treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic artery embolization
Description: Using a unilateral femoral approach, selective catheterization of the hepatic artery will be performed. Vascular access is obtained via the common femoral artery and a guide-wire advanced under fluoroscopic guidance. A microcatheter is then inserted over the guide-wire. The superior mesenteric artery is selected and an angiogram performed to identify any aberrant arterial anatomy and verify antegrade portal vein flow. The celiac axis is then selected and an angiogram completed. The catheter and guide-wire are used to select the proper hepatic artery and a limited angiogram performed to identify the branches of the hepatic artery. The right or left hepatic artery is selected distal to the cystic artery (if visualized), depending on the location of the lesions to be treated. The LC Bead, loaded with irinotecan will be delivered into the artery.
Study: NCT04131725

Intervention type: DEVICE
Intervention: Cardiac Performance System (NSR)
Description: Device: Cardiac Performance System Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function. The device will be worn at the time when Pulmonary Artery Catheter procedures are conducted.
Study: NCT01713608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: OZ439 x mg once daily for 3 days with milk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: OZ439 x mg once daily for 3 days with milk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: OZ439 x mg once daily for 3 days with milk
Study: NCT01268020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FMH3
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not \>10% of 5 mCi limit) or 2 ug of \[18F\]-FMH3, whichever is greatest.
Study: NCT01987635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEMO 3D ring
Description: The experimental MEMO 3D ring is placed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard use of rigid ring.
Description: The rigid ring is placed, which is standard procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Echocardiography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D Echocardiography
Study: NCT00513656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone
Study: NCT01254331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra]
Description: tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
Study: NCT03488355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified laboratory report
Description: Report from microbiology laboratory: This POSITIVE urine culture collected from an indwelling catheter may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call the microbiology laboratory for identification and susceptibility results.
Study: NCT00516074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day
Study: NCT04382092

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FilmArray Pneumonia
Description: Respiratory samples are treated according to routine laboratory testing : culture, immuno assays AND molecular testing (FilmArray PNEU) of the endotracheal aspirate sample 24 hours a day.
Study: NCT00329420

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 400 mg at Weeks 0, 2 and 4.
Study: NCT00756340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * Bevacizumab IV every 2 weeks~* Dose Level 0- 8 mg/kg~* Dose Level 1 (starting dose)- 10 mg/kg~* Dose Level 2- 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: * Everolimus~* Dose Level 0- 4 mg/m2~* Dose level 1 (starting dose)- 4 mg/m2~* Dose Level 2- 5 mg/m2
Study: NCT00516074

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous injection, volume equivalent to active, twice a day
Study: NCT04365868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belapectin
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belapectin
Description: intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous
Study: NCT00098956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV
Study: NCT01141452

Intervention type: DRUG
Intervention: Extra-fine hydrofluoroalkane beclomethasone MDI
Description: Step-up in baseline BDP-equivalent ICS dose

Intervention type: DRUG
Intervention: Chlorofluorocarbon beclomethasone metered dose inhaler
Description: Step-up in baseline BDP-equivalent ICS dose

Intervention type: DRUG
Intervention: Fluticasone propionate metred dose inhaler
Description: Step-up in baseline BDP-equivalent ICS dose

Intervention type: DRUG
Intervention: Fluticasone propionate metred dose inhaler
Description: Initiation of ICS therapy

Intervention type: DRUG
Intervention: Hydrofluoroalkane beclomethasone metred dose inhaler
Description: Initiation of ICS therapy

Intervention type: DRUG
Intervention: Chlorofluorocarbon beclomethasone dipropionate
Description: Initiation of ICS therapy
Study: NCT00968890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemrix (Influenza vaccine GSK2340272A)
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemrix (Influenza vaccine GSK2340272A)
Description: Intramuscular injection, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection, 1 dose
Study: NCT03350750

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: programmable CSF shunt valve
Description: Brain shunt surgery using a programmable CSF shunt valve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: programmable CSF shunt valve
Description: Brain shunt surgery using a programmable CSF shunt valve